In addition, the MUC4-ErbB2-ERK pathway has been shown to contribute to the characteristic resistance of PDC to gemcitabine by inhibiting the activation of intrinsic apoptosis in cancer cells [62, 63]. This evidence concerns the gene MUC4 and cancer.